FDA approves Gilead's seladelpar for primary biliary cholangitis

Gilead Sciences has secured FDA approval for Livdelzi (seladelpar), bolstering its liver disease portfolio amid a challenging landscape in oncology. The oral PPAR-delta agonist received accelerated approval on Wednesday to treat primary biliary cholangitis (PBC) in adults, either in combination with ursodeoxycholic acid (UDCA) or as monotherapy for those intolerant to UDCA.